Polyrizon Ltd. (PLRZ) Stock Price, Quote & News

Company Profile

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza blockers. Polyrizon Ltd. was incorp...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 9 374 0120

Website: www.polyrizon-biotech.com

Address:

5 Ha-Tidhar Street, Ra'anana, Israel

Digitalization2026 Apr. 2 at 8:44 PM

$SRXH 👀 After Hours Top Gainers PT2 $YAAS $IMTE $PCSA $PLRZ

0 · Reply

topstockalerts Apr. 2 at 8:33 PM

After Hours Top Gainers PT2 $YAAS $IMTE $PCSA $PLRZ $PMAX

0 · Reply

WorldwideWesley Apr. 1 at 1:24 PM

$LNKS you can implement an r/s and still have a sub $1 price. $PLRZ last year split around $0.75!

0 · Reply

LORDG00N Mar. 30 at 5:33 PM

$PLRZ i texted the CEO, told him that we want some news about their nasal spray

0 · Reply

LORDG00N Mar. 30 at 3:09 PM

$ELAB SHOULD GO BUY $PLRZ its cheap right now +20% at least during the week for sure

0 · Reply

LORDG00N Mar. 30 at 2:35 PM

$PLRZ someone should texte them

0 · Reply

OwlKing Mar. 29 at 6:10 PM

$BLMZ $PLRZ $BTCT $BTOG JK

0 · Reply

TradeWithCreed Mar. 27 at 8:21 PM

$PLRZ $BLMZ $BTCT $BTOG crypto

0 · Reply

Tbirdyguy Mar. 27 at 8:02 PM

$PLRZ fuck this stock can't believe I'm still holding this trash, they got nothing, Israeli company spending their time investing in drones instead of pushing pharma products and look at this absolute ship price action for the past 3 months

0 · Reply

ORDOVA Mar. 27 at 8:01 AM

$PLRZ https://www.globenewswire.com/news-release/2026/03/26/3263127/0/en/Polyrizon-Provides-2025-and-Recent-Highlights.html

1 · Reply

Polyrizon Provides 2025 and Recent Highlights

Mar 25, 2026, 5:25 PM EDT - 10 days ago

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

Mar 24, 2026, 8:47 AM EDT - 12 days ago

Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications

Mar 17, 2026, 8:25 AM EDT - 19 days ago

Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program

Mar 10, 2026, 7:55 AM EDT - 26 days ago

Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study

Feb 26, 2026, 8:12 AM EST - 5 weeks ago

Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product

Feb 17, 2026, 11:32 AM EST - 6 weeks ago

Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker

Feb 10, 2026, 6:55 AM EST - 7 weeks ago

Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator

Feb 6, 2026, 7:55 AM EST - 2 months ago

Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation

Feb 4, 2026, 7:12 AM EST - 2 months ago

Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company

Jan 22, 2026, 9:25 AM EST - 2 months ago

Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX™ Allergy Blocker

Jan 13, 2026, 8:39 AM EST - 2 months ago

Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet

Jan 8, 2026, 8:45 AM EST - 3 months ago

Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX™

Jan 5, 2026, 9:07 AM EST - 3 months ago

Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator

Jan 2, 2026, 8:30 AM EST - 3 months ago

As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated

Dec 29, 2025, 7:20 AM EST - 3 months ago

Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet

Dec 19, 2025, 8:20 AM EST - 3 months ago

Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses

Dec 11, 2025, 8:15 AM EST - 4 months ago

Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program

Dec 8, 2025, 8:55 AM EST - 4 months ago

Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray

Dec 4, 2025, 7:32 AM EST - 4 months ago

From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection

Dec 3, 2025, 9:28 AM EST - 4 months ago

Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product

Dec 2, 2025, 7:55 AM EST - 4 months ago

Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform

Nov 6, 2025, 8:55 AM EST - 5 months ago

Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation

Oct 6, 2025, 8:21 AM EDT - 6 months ago

Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy

Sep 19, 2025, 8:15 AM EDT - 7 months ago

Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker

Sep 12, 2025, 7:26 AM EDT - 7 months ago

Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study

Aug 14, 2025, 8:14 AM EDT - 8 months ago

Polyrizon Regains Compliance with Nasdaq Listing Requirements

Jul 15, 2025, 7:55 AM EDT - 9 months ago

Polyrizon Retains Nasdaq Listing Following Hearings Panel

Jun 12, 2025, 7:32 AM EDT - 10 months ago

Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics

May 23, 2025, 4:15 PM EDT - 11 months ago

Polyrizon Announces Receipt of Nasdaq Delisting Notice

May 21, 2025, 7:10 AM EDT - 11 months ago

Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform

May 13, 2025, 7:45 AM EDT - 11 months ago

Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment

Apr 25, 2025, 7:37 AM EDT - 1 year ago

Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model

Apr 11, 2025, 4:15 PM EDT - 1 year ago

Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements

Apr 2, 2025, 9:05 AM EDT - 1 year ago

Polyrizon Engages Leading Branding Firm for Strategic Brand Development

Apr 1, 2025, 4:09 PM EDT - 1 year ago

Polyrizon Ltd. Announces Closing of $17.0 Million Private Placement

Mar 31, 2025, 9:32 AM EDT - 1 year ago

Polyrizon Ltd. Announces $17.0 Million Private Placement

Mar 27, 2025, 8:25 AM EDT - 1 year ago

Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting

Mar 25, 2025, 4:04 PM EDT - 1 year ago

Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment

Mar 14, 2025, 8:35 AM EDT - 1 year ago

Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments

Mar 13, 2025, 7:51 AM EDT - 1 year ago

Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform

Mar 11, 2025, 4:27 PM EDT - 1 year ago

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Mar 10, 2025, 7:47 AM EDT - 1 year ago

Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform

Jan 30, 2025, 5:55 AM EST - 1 year ago

Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform

Jan 23, 2025, 6:40 AM EST - 1 year ago

Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Dec 30, 2024, 6:25 AM EST - 1 year ago

Polyrizon Announces Publication of U.S. National Patent Application for Its Innovative Hydrogel Nasal Technologies

Dec 19, 2024, 7:22 AM EST - 1 year ago

Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs

Dec 18, 2024, 6:25 AM EST - 1 year ago

Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker

Dec 13, 2024, 6:25 AM EST - 1 year ago

Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance

Dec 2, 2024, 8:02 AM EST - 1 year ago

Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

Digitalization2026 Apr. 2 at 8:44 PM

$SRXH 👀 After Hours Top Gainers PT2 $YAAS $IMTE $PCSA $PLRZ

0 · Reply

topstockalerts Apr. 2 at 8:33 PM

After Hours Top Gainers PT2 $YAAS $IMTE $PCSA $PLRZ $PMAX

0 · Reply

WorldwideWesley Apr. 1 at 1:24 PM

$LNKS you can implement an r/s and still have a sub $1 price. $PLRZ last year split around $0.75!

0 · Reply

LORDG00N Mar. 30 at 5:33 PM

$PLRZ i texted the CEO, told him that we want some news about their nasal spray

0 · Reply

LORDG00N Mar. 30 at 3:09 PM

$ELAB SHOULD GO BUY $PLRZ its cheap right now +20% at least during the week for sure

0 · Reply

LORDG00N Mar. 30 at 2:35 PM

$PLRZ someone should texte them

0 · Reply

OwlKing Mar. 29 at 6:10 PM

$BLMZ $PLRZ $BTCT $BTOG JK

0 · Reply

TradeWithCreed Mar. 27 at 8:21 PM

$PLRZ $BLMZ $BTCT $BTOG crypto

0 · Reply

Tbirdyguy Mar. 27 at 8:02 PM

0 · Reply

ORDOVA Mar. 27 at 8:01 AM

$PLRZ https://www.globenewswire.com/news-release/2026/03/26/3263127/0/en/Polyrizon-Provides-2025-and-Recent-Highlights.html

1 · Reply

ORDOVA Mar. 25 at 2:04 PM

$PLRZ https://investor.polyrizon-biotech.com/pressreleases/detail/43539275-d428-41b1-bb64-745d8ba57a51?cikNumber=1893645

0 · Reply

prismmarketview Mar. 24 at 3:39 PM

Polyrizon $PLRZ Targets eVTOL Drone Market With Planned Stake in Colugo https://prismmarketview.com/polyrizon-targets-evtol-drone-market-with-planned-stake-in-colugo/

0 · Reply

LORDG00N Mar. 24 at 2:58 PM

$PLRZ

0 · Reply

LegionOfBoom Mar. 24 at 12:58 PM

$PLRZ

0 · Reply

teamgreen Mar. 24 at 12:48 PM

$PLRZ

0 · Reply

Stock_Catcher Mar. 24 at 12:47 PM

$PLRZ Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications

0 · Reply

Rampageusa Mar. 18 at 9:36 PM

$PLRZ 100$ stock, 20-30$ on any good market day, not sure if that’s coming..hoping soon.

0 · Reply

soontobemillion Mar. 18 at 2:31 PM

$PLRZ look at EONR

0 · Reply

theflynews Mar. 17 at 3:47 PM

Biotech Alert: Searches spiking for these stocks today - $PLRZ - https://thefly.com/PLRZ

0 · Reply

ORDOVA Mar. 17 at 2:48 PM

$PLRZ https://finance.yahoo.com/news/polyrizon-signs-agreement-leading-global-122500732.html

0 · Reply

DARKP00L Mar. 17 at 12:28 PM

$PLRZ 08:27 on Mar. 17 2026 Polyrizon Signs Deal With Contract Research Organization To Carry Out Package Of Preclinical Biocompatibility Studies In Accordance With ISO 10993 Standards, GLP Requirements #tradeideas

0 · Reply

Stock_Catcher Mar. 17 at 12:26 PM

$PLRZ Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program

0 · Reply

Market Cap	N/A
Revenue (ttm)	N/A
Net Income (ttm)	N/A
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	1,429,814
Avg Vol	N/A
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	N/A
Beta	N/A
Analysts	N/A
Price Target	N/A